Current Report Filing (8-k)
March 14 2017 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 14, 2017
Arena Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
000-31161
|
23-2908305
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
6154 Nancy Ridge Drive,
San Diego, CA
|
|
92121
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code: (858) 453-7200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
In this report, “Arena Pharmaceuticals,” “Arena,” “Comp
any,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and/or one or more of our wholly owned subsidiaries, unless the context otherwise provides. Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.
Item 2.02
R
e
sults
of
O
perat
i
o
n
s and
Financial
Con
d
itio
n
.
On March 14, 2017, we issued a press release report
i
ng our f
i
n
a
nc
i
al resul
t
s for
t
he fourth quar
t
er
and full year
ended December 31, 2016. The f
u
ll
t
ext of
the press re
l
ease is furnished as E
x
hi
b
it 99.1
t
o th
i
s Current Rep
o
rt on Form 8-K.
Item 9.01 Financi
a
l Statements and
Exh
i
b
i
ts. (d)
E
xhibits.
99.1
Press
release issued March 14, 2017, rep
o
r
t
i
n
g f
ina
n
c
ia
l
res
u
lt
s
fo
r
th
e fourth q
ua
r
te
r
and full year
en
d
ed December
3
1,
2
0
16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Date: March 14, 2017
|
Arena Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
By:
|
|
/s/ Amit Munshi
|
|
|
|
|
Amit Munshi
|
|
|
|
|
President and Chief Executive Officer
|
Exhibit
Index
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press release issued March 14, 2017, reporting financial results for the fourth quarter and full year ended December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Apr 2023 to Apr 2024
